NCT06864000 Phenotypic and Molecular Characterisation of Cerebral Amyloid Angiopathy
| NCT ID | NCT06864000 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University Hospital, Rouen |
| Condition | Cerebral Amyloid Aβ Angiopathy |
| Study Type | OBSERVATIONAL |
| Enrollment | 100 participants |
| Start Date | 2023-03-31 |
| Primary Completion | 2027-07-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 100 participants in total. It began in 2023-03-31 with a primary completion date of 2027-07-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Cerebral Aβ amyloid angiopathy is a severe disease characterised by amyloid deposits in the cerebral vessels, manifested mainly by recurrent cerebral haematomas and cognitive impairment. Diagnostic criteria are based on brain imaging, but the usefulness of this imaging in predicting the course of the disease remains undetermined. The genetic component is largely understudied. Less than 5% of patients carry mutations or duplications of the APP gene. Susceptibility factors such as APOE genotypes and rare variants recently discovered in Alzheimer's disease within the SORL1, TREM2 or ABCA7, ABCA1 and ATP8B4 genes could play a role in the pathophysiology of cerebral amyloid angiopathy. There is currently no specific treatment available. Based on a national recruitment of patients with cerebral amyloid angiopathy, this project aims to assess the role of genetic variants in the diagnosis and progression of cerebral amyloid angiopathy. A better understanding of the mechanisms, particularly genetic, could help us to develop treatments in the era of gene therapy.
Eligibility Criteria
Inclusion Criteria: * Patients with a diagnosis of cerebral amyloid angiopathy (CAA) whose genetic samples are initially sent to the Rouen or Paris-Lariboisière genetics laboratories for molecular diagnosis of a genetic cause, thanks to national recruitment and for whom the patients consent to continuing genetic analyses for research purposes without feedback. * Diagnosis of cerebral amyloid angiopathy (CAA) certain or probable according to the modified Boston diagnostic criteria (1) (except age) * Age of onset of symptoms \<66 years * Absence of APP mutation/duplication (analysis must already have been carried out in the laboratory on receipt of the sample as part of routine care) * Signed consent for research * Patient covered by a social security scheme Exclusion Criteria: * Age at first neurological symptom \> 66 years * Minor patients * Other differential diagnosis that better explains the clinical situation * Identification of mutations or duplication of the APP gene * AAC possible but not probable according to the revised Boston criteria * Patient deprived of liberty by judicial or administrative decision
Contact & Investigator
Lou LG GRANGEON, Doctor
PRINCIPAL INVESTIGATOR
University Rouen Hospital
Frequently Asked Questions
Who can join the NCT06864000 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 99 Years, studying Cerebral Amyloid Aβ Angiopathy. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06864000 currently recruiting?
Yes, NCT06864000 is actively recruiting participants. Contact the research team at Secretariat.DRC@chu-rouen.fr for enrollment information.
Where is the NCT06864000 trial being conducted?
This trial is being conducted at Rouen, France.
Who is sponsoring the NCT06864000 clinical trial?
NCT06864000 is sponsored by University Hospital, Rouen. The principal investigator is Lou LG GRANGEON, Doctor at University Rouen Hospital. The trial plans to enroll 100 participants.